Prevalence of Hyperapolipoprotein B and Associations with Other Cardiovascular Risk Factors Among Human Immunodeficiency Virus–Infected Patients in Pernambuco, Brazil

Carvalho, Érico Higino de; Filho, Demócrito de Barros Miranda; Ximenes, Ricardo Arraes de Alencar; Albuquerque, Maria de Fátima Pessoa Militão de; Melo, Heloísa Ramos Lacerda de; Gelenske, Thais; Medeiros, Zoraya de Barros; Montarroyos, Ulísses Ramos; Bandeira, Francisco

doi:10.1089/met.2009.0092

Cited by 12 publications

(10 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Differences in metabolic risk factors, which may reflect the atherogenic profile, described for PLWHIV living in Recife were associated with high cardiovascular risk [26,27]. A previous study in Recife demonstrated an increased prevalence of hyperapolipoprotein B, which was associated with prolonged use of antiretroviral therapy, hypertriglyceridemia, insulin resistance, diabetes, and a past history of hypertension; hyperapolipoprotein B was higher among patients with metabolic syndrome and higher Framingham scores [28]. Interestingly, in the Rio Grande do Sul group, there was a higher proportion of overweight and obese individuals than in the other two states, although there was a smaller proportion of individuals with metabolic syndrome.…”

Section: Discussionmentioning

confidence: 89%

Comparison between potential risk factors for cardiovascular disease in people living with HIV/AIDS in areas of Brazil

Ximenes

Lacerda

Miranda-Filho

et al. 2015

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Coronary heart disease and its risk factors depend on genetic characteristics, behaviors, and habits, all of which vary in different regions. The use of antiretroviral therapy (ARV) has increased the survival of people living with HIV/AIDS (PLWHA), who begin to present mortality indicators similar to the general population. This study aimed to compare the prevalence of factors potentially associated with coronary heart disease in three cohorts of PLWHA from three different regions of Brazil. Methodology: The study population was composed of participants of the cohorts of Pernambuco, Goiás, and Rio Grande do Sul states. In these sites, adult patients attending reference centers for treatment of HIV/AIDS were consecutively enrolled. Results: Pernambuco and Goiás had a higher proportion of males and of individuals with high-risk high-density lipoprotein (HDL). Pernambuco also had a greater proportion of individuals with hypertension, elevated triglycerides, and CD4 counts below 200 cells/mm 3 . Lower education was more frequent in Rio Grande do Sul, and the use of cocaine was higher in this state. Conclusions: The results confirm the importance of risk factors for coronary heart disease in PLHIV and highlight differences in the three cohorts. Specific measures against smoking and sedentary lifestyle, avoidance of advanced stages of immunosuppression, and appropriate treatment of dyslipidemia and dysglicemia are urgently needed to cope with the disease in Brazil.

show abstract

Section: Discussionmentioning

confidence: 89%

Comparison between potential risk factors for cardiovascular disease in people living with HIV/AIDS in areas of Brazil

Ximenes

Lacerda

Miranda-Filho

et al. 2015

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Other methods used for lipodystrophy diagnosis in these studies were patient selfreport alone (n=4) [17,20,21,28]; clinician diagnosis associated with body measurements (n=1) [22]; patient self-report associated with body measurements (n=2) [30,31]; and clinician diagnosis alone (n=2) [24,25].…”

Section: Synthesis Of Resultsmentioning

confidence: 99%

“…Not all the surveyed patients developed lipodystrophy associated with HIV [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31], which suggests that lipodystrophy syndrome varies not only with respect to the length of time of the treatment regimen, but also in relation to the effects of systemic chronic inflammatory process resulting from HIV infection itself and factors associated with lifestyle such as physical activity, dietary pattern, and other factors [23,36,37]. There are few studies in the literature comparing these changes with those of non-HIV-infected individuals, because a fat gain can happen with natural aging, or as an immune recovery process after initiation of HAART regimen [38,39].…”

Section: Discussionmentioning

confidence: 99%

“…Table 1 shows the characteristics of the Brazilian studies included in the review with estimates of prevalence of lipodystrophy in people living with HIV. With regard to the study design, 14 were crosssectional studies [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31], and 1 was a retrospective cohort study [19].…”

Section: Study Selectionmentioning

confidence: 99%

“…The remaining papers were intended to assess metabolic changes, and lipodystrophy was a secondary outcome [19][20][21][22][24][25][26][27][28].…”

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of HIV-Associated Lipodystrophy in Brazil: A Systematic Review of the Literature

Justina¹,

Trevisol²,

Schuelter‐Trevisol³

2014

J AIDS Clin Res

View full text Add to dashboard Cite

Safety and Efficacy of Weight‐Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug‐Drug Interactions with Antiretroviral Therapy

Cope¹,

Fischetti²,

Kavanagh

et al. 2019

Pharmacotherapy

View full text Add to dashboard Cite

The prevalence of obesity among persons living with human immunodeficiency virus (HIV) has increased significantly and may be linked to the use of antiretroviral therapy. Although weight‐loss medications approved by the U.S. Food and Drug Administration are recommended as an adjunct to diet and exercise to treat obesity in the general population, little is known about the safety and efficacy of these drugs specifically in persons living with HIV. We review the available evidence regarding the effective use of weight‐loss pharmacotherapy in persons living with HIV and its potential to interact with antiretroviral therapy. Persons living with HIV are frequently not reported or included in clinical trials for weight‐loss medications; however, treatment efficacy is likely similar to the general population. Several important reported or theoretical drug‐drug interactions exist between antiobesity pharmacotherapy and antiretroviral therapy. Orlistat is a weight‐loss drug available in the United States without a prescription and was linked to HIV viral rebound in several case reports. Clinicians should be aware of the potential for loss of HIV viremia control when certain weight‐loss pharmacotherapies are used in combination with antiretrovirals.

show abstract

Prevalence of Hyperapolipoprotein B and Associations with Other Cardiovascular Risk Factors Among Human Immunodeficiency Virus–Infected Patients in Pernambuco, Brazil

Cited by 12 publications

References 56 publications

Comparison between potential risk factors for cardiovascular disease in people living with HIV/AIDS in areas of Brazil

Comparison between potential risk factors for cardiovascular disease in people living with HIV/AIDS in areas of Brazil

Prevalence of HIV-Associated Lipodystrophy in Brazil: A Systematic Review of the Literature

Safety and Efficacy of Weight‐Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug‐Drug Interactions with Antiretroviral Therapy

Contact Info

Product

Resources

About